Efficacy and Safety of Arbidol (umifenovir) in Patients with COVID-19: A Systematic Review and Meta-analysis

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2021 Aug 4

PMID 34347937

Citations 14

Authors

Behnam Amani

Bahman Amani

Sara Zareei

Mahsa Zareei

Affiliations

Soon will be listed here.

Abstract

Objective: To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID-19 treatment.

Methods: A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle-Ottawa scale were used to assess the quality of included studies. Meta-analysis was performed using RevMan 5.3.

Results: Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non-antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR-PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78-1.14) and Day 14 (RR: 1.10; 95% CI: 0.96-1.25), and PCR negative conversion time (PCR-NCT; mean difference [MD]: 0.74; 95% CI: -0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06-4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR-PCR on Day 7 and PCR-NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05).

Conclusion: The present meta-analysis showed no significant benefit of using arbidol compared with non-antiviral treatment or other therapeutic agents against COVID-19 disease. High-quality studies are needed to establish the efficacy and safety of arbidol for COVID-19.

Citing Articles

Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research.

Nie J, Xia H, Liu Y, Yu Y, Xu R Front Pharmacol. 2023; 14:1292354.

PMID: 38094891 PMC: 10716843. DOI: 10.3389/fphar.2023.1292354.

Effects of adjuvant ozone autohemotherapy combined with routine treatment on clinical and paraclinical features of mechanically ventilated COVID-19 patients in the intensive care unit: a pilot randomized controlled trial.

Aghamohammadi D, Shakouri S, Jahanpanah N, Dolatkhah N Med Gas Res. 2023; 14(2):67-74.

PMID: 37929510 PMC: 10715328. DOI: 10.4103/2045-9912.385439.

Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.

Girgis A, Panda S, Kariuki B, Bekheit M, Barghash R, Aboshouk D Molecules. 2023; 28(18).

PMID: 37764378 PMC: 10537473. DOI: 10.3390/molecules28186603.

Antiviral Therapy of COVID-19.

Gudima G, Kofiadi I, Shilovskiy I, Kudlay D, Khaitov M Int J Mol Sci. 2023; 24(10).

PMID: 37240213 PMC: 10218869. DOI: 10.3390/ijms24108867.

A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19.

Luo J, Zhang Z, Zhao S, Gao R Int J Mol Sci. 2023; 24(7).

PMID: 37047339 PMC: 10094131. DOI: 10.3390/ijms24076369.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

Zhong Q, Yang Z, Liu Y, Deng H, Xiao H, Shi L . Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol. 2009; 154(4):601-7. PMC: 7086808. DOI: 10.1007/s00705-009-0346-4. View

Yang C, Ke C, Yue D, Li W, Hu Z, Liu W . Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals. Front Public Health. 2020; 8:249. PMC: 7273930. DOI: 10.3389/fpubh.2020.00249. View

Fang J, Li H, Du W, Yu P, Guan Y, Ma S . Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study. Front Pharmacol. 2020; 11:560209. PMC: 7530276. DOI: 10.3389/fphar.2020.560209. View

Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q . Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020; 26(7):917-921. PMC: 7182750. DOI: 10.1016/j.cmi.2020.04.026. View

Lan X, Shao C, Zeng X, Wu Z, Xu Y . Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study. Int J Clin Pharmacol Ther. 2021; 59(5):378-385. DOI: 10.5414/CP203861. View

Paudel S, Dangal G, Chalise A, Bhandari T, Dangal O . The Coronavirus Pandemic: What Does the Evidence Show?. J Nepal Health Res Counc. 2020; 18(1):1-9. DOI: 10.33314/jnhrc.v18i1.2596. View

Zhang Y, Xu Q, Sun Z, Zhou L . Current targeted therapeutics against COVID-19: Based on first-line experience in China. Pharmacol Res. 2020; 157:104854. PMC: 7192075. DOI: 10.1016/j.phrs.2020.104854. View

Chen J, Lin S, Niu C, Xiao Q . Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med. 2020; 15(2):257-265. PMC: 7544967. DOI: 10.1080/17476348.2020.1822741. View

10.

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z . Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020; 93(1):481-490. PMC: 7361300. DOI: 10.1002/jmv.26256. View

11.

Delogu I, Pastorino B, Baronti C, Nougairede A, Bonnet E, de Lamballerie X . In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 2011; 90(3):99-107. DOI: 10.1016/j.antiviral.2011.03.182. View

12.

Blaising J, Polyak S, Pecheur E . Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; 107:84-94. PMC: 7113885. DOI: 10.1016/j.antiviral.2014.04.006. View

13.

Vankadari N . Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020; 56(2):105998. PMC: 7187825. DOI: 10.1016/j.ijantimicag.2020.105998. View

14.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

15.

Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T . Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020; 81(1):e21-e23. PMC: 7195393. DOI: 10.1016/j.jinf.2020.03.060. View

16.

Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B . COVID-19: A promising cure for the global panic. Sci Total Environ. 2020; 725:138277. PMC: 7128376. DOI: 10.1016/j.scitotenv.2020.138277. View

17.

Li M, Yu T, Zhu J, Wang Y, Yang Y, Zhao K . Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19. Ann Palliat Med. 2021; 10(3):3307-3312. DOI: 10.21037/apm-21-400. View

18.

Pecheur E, Lavillette D, Alcaras F, Molle J, Boriskin Y, Roberts M . Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry. 2007; 46(20):6050-9. PMC: 2532706. DOI: 10.1021/bi700181j. View

19.

Wen C, Xie Z, Li Y, Deng X, Chen X, Cao Y . [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019]. Zhonghua Nei Ke Za Zhi. 2020; 59(8):605-609. DOI: 10.3760/cma.j.cn112138-20200227-00147. View

20.

Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y . Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med. 2020; 1(1):105-113.e4. PMC: 7235585. DOI: 10.1016/j.medj.2020.04.001. View